For Some, Oral Insulin’s Allure Persists Despite Hurdles
This article was originally published in Pharmaceutical Approvals Monthly
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.
You may also be interested in...
Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India